- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Rheumatology :: Rheumatology Conferences
ACR 2007 Scientific Meeting
November 6-11, 2007 Boston, MA- Denosumab, certolizumab show promise as potential treatments in RA
- Etanercept provides sustained efficacy, improved patient-reported outcomes in AS
- Targeting the IL-6 cytokine pathway presents exciting opportunities in variety of disease states, experts report
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Tocilizumab improves function, QOL in patients with RA who respond inadequately to conventional DMARDs, researchers report
EULAR 2007 Annual Congress
June 13-16, 2007 Barcelona, Spain- Anti-TNF agents may slow, protect against RA-related joint destruction, disability, work loss
- Biologics represent useful treatment for PsA; other therapies, approaches require more study
- Certolizumab pegol improves signs, symptoms of RA among patients with insufficient response to methotrexate, study data show
- First-line anti-TNF agents yield high rate of long-term response, well tolerated in patients with AS, study demonstrates
- Patients with RA, PsA, AS who have not responded to etanercept, infliximab show response to adalimumab, according to subanalyses
- FDA accepts Pfizer's NDA for tofacitinib in RA for review
- Boehringer Ingelheim, AbGenomics terminate agreement to develop, commercialize therapeutic monoclonal antibody
- Anika Therapeutics licenses U.S. rights to Monovisc to DePuy Mitek
- Isotechnika, Vifor Pharma sign license agreement for development, commercialization of voclosporin
- GSK exercises option to license ChemoCentryx's investigational RA therapy
- UCB, Immunomedics restructure epratuzumab agreement
- UCB, Otsuka discontinue immunology collaboration, focus on development of CNS drugs in Japan
- Merck dissolves AD agreement with Acumen, signs PI3K inhibitor agreement with Exelixis
- UCB, Astellas agree to develop, commercialize certolizumab pegol for RA in Japan
- Isotechnika, Vifor Pharma sign license agreement for development, commercialization of voclosporin
